SARS-CoV-2 Vaccination Elicits Unconventional IgM Specific Responses in Naïve and Previously COVID19-Infected Individuals DOI
Alessandra Ruggiero, Chiara Piubelli, Lucia Calciano

et al.

SSRN Electronic Journal, Journal Year: 2021, Volume and Issue: unknown

Published: Jan. 1, 2021

Background: IgG antibodies specific for the SARS-CoV-2 Spike protein are under intensive investigation urgent need to identify a correlate of protective immunity in individuals vaccinated with licensed and candidate COVID-19 vaccines. Limited data available on vaccine-elicited IgM their potential implication SARS-CoV-2. Methods: We performed longitudinal study quantify spike (IgG-S IgM-S) 1873 health care worker (HCW) recipients BNT162b2 (Comirnaty) vaccine. Samples were collected before administration (T0), at second dose (T1) three weeks after (T2). The cohort included 1584 immunologically naïve (IN) 289 had history previous infection (PI). Findings: In IN we identified patterns responses: (a) positive/IgM negative (36.1%), (b) coordinated IgM-S/IgG-S responses appearing first (37.4%) (c) delayed (26.3%). Coordinated associated higher titers. Of PI vaccinees, 64.5% IgM-S positive vaccination, whereas 32% 3.5% developed vaccine respectively. sera pseudovirus neutralization titers compared negative. Similar results observed who received either Moderna or Astrazeneca. Interpretation: expression IgG-S vaccination was significantly more efficient response both antibody virus-neutralizing activity, representing protection. Instead, unconventional positive/IgM-S may be suggestive recruitment cross coronaviruses by warranting further investigation.Funding Information: This work supported Italian Ministry Health "Fondi Ricerca Corrente"- L1P5 "Progetto Finalizzata COVID-2020-12371675" IRCCS Sacro Cuore Don Calabria Hospital, FUR 2020 Department Excellence 2018-2022, MIUR, Italy Brain Research Foundation Verona. Declaration Interests: authors declare no competing interests.Ethics Approval Statement: University Verona biobank (Ethics Committee approval prot. N. 1538). Tropica Biobank Hospital 17985). All participants signed informed consent.

Language: Английский

An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection DOI Creative Commons

P.A. van der Ley,

Afshin Zariri,

Elly van Riet

et al.

Frontiers in Immunology, Journal Year: 2021, Volume and Issue: 12

Published: Dec. 17, 2021

The development of more effective, accessible, and easy to administer COVID-19 vaccines next the currently marketed mRNA, viral vector, whole inactivated virus is essential curtailing SARS-CoV-2 pandemic. A major concern reduced vaccine-induced immune protection emerging variants, therefore booster vaccinations broaden strengthen response might be required. Currently, all registered majority in are intramuscularly administered, targeting induction systemic immunity. Intranasal have capacity induce local mucosal immunity as well, thereby primary route entry with potential blocking transmission. Furthermore, intranasal offer greater practicality terms cost ease administration. only eight out 112 clinical administered intranasally. We developed an subunit vaccine, based on a recombinant, six-proline-stabilized, D614G spike protein (mC-Spike) linked via LPS-binding peptide sequence mCramp (mC) outer membrane vesicles (OMVs) from Neisseria meningitidis . was produced CHO cells, after linking OMVs, OMV-mC-Spike vaccine mice Syrian hamsters or intramuscular prime-boost vaccinations. In animals that received OMV-mC-Spike, serum-neutralizing antibodies were induced upon vaccination. Importantly, high levels spike-binding immunoglobulin G (IgG) (IgA) nose lungs detected intranasally vaccinated animals, whereas vaccination IgG serum. Two weeks their second vaccination, challenged protected weight loss replication compared control groups OMV alone. Histopathology showed no lesions 7 days challenge OMV-mC-Spike-vaccinated hamsters, did show pathological lung. candidate data very promising support further this novel non-replicating, needle-free, concept for testing.

Language: Английский

Citations

91
Innovative design of bacterial outer membrane vesicles for vaccine development DOI

Qinzhen Cheng,

Gaoli Niu,

Yiling He

et al.

Nano Today, Journal Year: 2025, Volume and Issue: 61, P. 102650 - 102650

Published: Feb. 1, 2025

Language: Английский

Citations

0
Next-Generation Coronavirus Disease 2019 Vaccines DOI
Kathryn E. Stephenson

Infectious Disease Clinics of North America, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0
Toward a SARS-CoV-2 VLP Vaccine: HBc/G as a Carrier for SARS-CoV-2 Spike RBM and Nucleocapsid Protein-Derived Peptides DOI Creative Commons
Ivars Petrovskis, Dace Skrastiņa, Juris Jansons

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(3), P. 267 - 267

Published: March 4, 2024

Virus-like particles (VLPs) offer an attractive possibility for the development of vaccines. Recombinant core antigen (HBc) Hepatitis B virus (HBV) was expressed in different systems, and E. coli expression system shown to be effective production HBc VLPs. Here, we used HBV genotype G (HBc/G) as a technologically promising VLP carrier presentation spike RBM nucleocapsid protein-derived peptides SARS-CoV-2 Delta variant subsequent immunological evaluations obtained fusion proteins. The major immunodominant region (MIR) HBc/G protein modified through insertion receptor binding motif (RBM) from S or B-cell epitope-containing peptide N protein. C-terminus two truncated proteins group five cytotoxic T lymphocyte (CTL) epitopes After coli, MIR-derived were found insoluble recovered step-wise solubilization with urea, followed by refolding. Despite lack correct VLPs, chimeric induced high levels antibodies BALB/c mice. These specifically recognized either eukaryotically hRBD bacterially (2–220) SARS-CoV-2. CTL-epitope-containing purified cytokines analyzed flow cytometry after stimulation T-cells target CTL peptides. Only deleted polyarginine (PA) domain able induce specific activation T-cells. At same time, T-cell response against detected both neutralization pseudotyped murine retrovirus anti-HBc/G-RBM sera low.

Language: Английский

Citations

1
Beta Spike-Presenting SARS-CoV-2 Virus-Like Particle Vaccine Confers Broad Protection against Other VOCs in Mice DOI Open Access
Irfan Ullah, Kelly Symmes,

Kadiatou Keita

et al.

Published: June 13, 2024

Vaccine antigens must present the correct conformation of viral fusion glycoproteins to elicit effective immune responses. Virus-like particles (VLPs) serve as promising vaccine platforms because they mimic membrane-embedded conformations on native viruses. Here, we employed SARS-CoV-2 VLPs (SMEN) presenting ancestral, Beta, or Omicron spikes identify variant that elicits potent and cross-protective responses in highly sensitive K18-hACE2 mouse model. A combined intranasal intramuscular administration regimen SMEN generated was predominantly mediated by antibodies with minor contributions from T cells. Immunization an ancestral spike resulted 100, 75, 0% protection against Delta Beta VOC-induced mortality, respectively, whereas most divergent provided only limited (50%, 0%, 25%) Delta, variants, respectively. By contrast, a offered 100% variants used this study. Thus, not overcame immunity produced other but also elicited diverse response. Our findings suggest leveraging protein can enhance immunity, potentially leading more comprehensive emerging variants.

Language: Английский

Citations

1
Bacterial Membrane Vesicles as a Novel Vaccine Platform against SARS-CoV-2 DOI
Çiğdem Yılmaz Çolak

Current Microbiology, Journal Year: 2024, Volume and Issue: 81(10)

Published: Aug. 20, 2024

Language: Английский

Citations

0
SARS-CoV-2 Vaccination Elicits Unconventional IgM Specific Responses in Naïve and Previously COVID19-Infected Individuals DOI
Alessandra Ruggiero, Chiara Piubelli, Lucia Calciano

et al.

SSRN Electronic Journal, Journal Year: 2021, Volume and Issue: unknown

Published: Jan. 1, 2021

Background: IgG antibodies specific for the SARS-CoV-2 Spike protein are under intensive investigation urgent need to identify a correlate of protective immunity in individuals vaccinated with licensed and candidate COVID-19 vaccines. Limited data available on vaccine-elicited IgM their potential implication SARS-CoV-2. Methods: We performed longitudinal study quantify spike (IgG-S IgM-S) 1873 health care worker (HCW) recipients BNT162b2 (Comirnaty) vaccine. Samples were collected before administration (T0), at second dose (T1) three weeks after (T2). The cohort included 1584 immunologically naïve (IN) 289 had history previous infection (PI). Findings: In IN we identified patterns responses: (a) positive/IgM negative (36.1%), (b) coordinated IgM-S/IgG-S responses appearing first (37.4%) (c) delayed (26.3%). Coordinated associated higher titers. Of PI vaccinees, 64.5% IgM-S positive vaccination, whereas 32% 3.5% developed vaccine respectively. sera pseudovirus neutralization titers compared negative. Similar results observed who received either Moderna or Astrazeneca. Interpretation: expression IgG-S vaccination was significantly more efficient response both antibody virus-neutralizing activity, representing protection. Instead, unconventional positive/IgM-S may be suggestive recruitment cross coronaviruses by warranting further investigation.Funding Information: This work supported Italian Ministry Health "Fondi Ricerca Corrente"- L1P5 "Progetto Finalizzata COVID-2020-12371675" IRCCS Sacro Cuore Don Calabria Hospital, FUR 2020 Department Excellence 2018-2022, MIUR, Italy Brain Research Foundation Verona. Declaration Interests: authors declare no competing interests.Ethics Approval Statement: University Verona biobank (Ethics Committee approval prot. N. 1538). Tropica Biobank Hospital 17985). All participants signed informed consent.

Language: Английский

Citations

0